


**Product Name** : NFX-179  
**Cat. No.** : PC-21237  
**CAS No.** : 2252314-46-6  
**Molecular Formula** : C<sub>17</sub>H<sub>16</sub>FIN<sub>4</sub>O<sub>3</sub>  
**Molecular Weight** : 470.24  
**Target** : MEK (MAP2K)  
**Solubility** : 10 mM in DMSO



CAS: 2252314-46-6

## Biological Activity

NFX-179 (Nedometinib, NFX179) is a potent, specific, topical, metabolically labile **MEK1/2** inhibitor with biochemical IC<sub>50</sub> of 135 nM (MEK1).

NFX-179 is specific for MEK1 inhibition and does not have substantial interactions across a panel of more than 150 kinases or a separate panel of 44 targets of particular relevance for neurological or cardiac toxicity.

NFX-179 potently inhibits phosphorylated-ERK (p-ERK) expression in a malignant peripheral nerve sheath tumor cell line HCT116 (KRAS-mutant G13D) and A375 (BRAF-mutant V600E) with IC<sub>50</sub> of 164 nM and 12 nM, respectively.

NFX-179 gel (topical application) significantly reduced the formation of new cSCCs in ultraviolet-induced cSCC mouse models.

NFX-179 inhibits the growth of human SCC cell lines in a dose-dependent manner, and topical NFX-179 application penetrates human skin and inhibits MAPK signaling in human cutaneous squamous cell carcinoma (cSCC) explants.

## References

Sarin KY, et al. *Sci Transl Med*. 2023 Oct 11;15(717):eade1844.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com